How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable

In this segment, our panel explains the mechanism of bispecific T-cell engager therapy and why it works differently from every other approach that has been tried in uveal melanoma. You will hear how tebentafusp physically redirects T cells to the tumor regardless of pre-existing immune recognition, why that approach is particularly well suited to a disease with low mutational burden and limited endogenous immune priming, and why HLA-A*02:01 positivity is not simply a label requirement but a biological necessity for this mechanism to function. The panel also discusses the rationale for treating earlier when tumor burden is lower, and prepares you for the distinctive toxicity profile that follows from the drug's activity against normal melanocytes throughout the body.